Luitpold Pharmaceuticals earns its gold from the businesses
of drugs and medical devices. Luitpold markets and
manufactures injectable products used to treat an array
of ailments including kidney disease. Luitpold also
manufactures materials used in dental bone grafting and bone
regeneration and treatments for equine and canine joint diseases.
The company, which targets its products primarily to
hospitals and clinics in US and Canadian
markets, operates through three divisions: American Regent,
Animal Health, and Osteohealth. It is also a contract manufacturer.
Originally a German company named after a Bavarian prince, Luitpold
is a subsidiary of one of Japan's largest
pharmaceutical companies, Daiichi Sankyo.
Luitpold's main business divisions constitute the bulk of
the company's operations. American Regent, Luitpold's oldest
division, develops and manufactures about 130 injectable products,
including its successful drug Venofer, used to treat chronic kidney
disease. The company expanded American Regent's
manufacturing capacity and diversified its product
offerings through the 2009 acquisition of US injectables maker
PharmaForce. Similar to the American Regent unit, the contract
manufacturing branch produces parenteral (injectable or
I.V.) medications which are used to dilute medications
or rehydrate patients.
The Osteohealth division markets and manufactures products used
for bone repair and growth. Made out of portions of animal (cattle)
bones, Luitpold's Bio-Oss branded product is used as a bone
substitute in grafting procedures. Luitpold also markets a
synthetic bone-regenerating product known as GEM 21S. In 2008,
Luitpold bought ownership of and marketing rights to GEM 21S from
its original developer, BioMimetic
Therapeutics. The unit also makes Heli-Product, wound
healing dressings with natural collagen.
Luitpold also makes products for horses and dogs through
its Luitpold Animal Health
division. The division's primary
product, Adequan, is manufactured in various forms and
treats arthritis and degenerative joint diseases in these
Luitpold is currently developing a molecular-level
technology (Targaceutical) that
the company believes will enable them to develop new therapies and
enhance the performance of their existing injectable
technology involves attaching a molecule to an existing
pharmaceutical agent; the addition of the molecule helps the
pharmaceutical attach to tissue. The company says the
technology has the potential to reduce toxicity and improve
delivery of drugs in the body.
▲ Show Less▼ Show Full Description